Mechanisms of immunotherapy resistance in small cell lung cancer
Open Access
- 28 December 2024
- journal article
- research article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 7, 55
Abstract
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a poor prognosis. Although the addition of immunotherapy to chemotherapy has modestly improved outcomes, most patients rapidly develop resistance. Resistance to immunotherapy can be broadly categorized into primary resistance and acquired resistance, as proposed by the Society for Immunotherapy of Cancer (SITC) consensus definition. Primary resistance occurs in the setting of failure to respond to immune checkpoint inhibitors (ICIs), while acquired resistance develops after initial response. The mechanisms of acquired and primary resistance to ICI are not well understood in SCLC, denoting an area of critical unmet need. Both intrinsic and extrinsic mechanisms play significant roles in immunotherapy resistance. Intrinsic mechanisms include defects in antigen presentation, mutations in key genes, reduced tumor immunogenicity, and epigenetic alterations. Extrinsic mechanisms involve the tumor microenvironment (TME), which is a complex interplay of both tumor- and immunosuppressive immune cells, vasculature, and microbiome. An understanding of these resistance mechanisms is crucial for developing novel therapeutic strategies to advance effective immunotherapy in patients with SCLC, a critical area of unmet need.Keywords
This publication has 129 references indexed in Scilit:
- Advances in immune checkpoint inhibitors therapy for small cell lung cancerCancer Medicine, 2023
- Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityJAMA Network Open, 2023
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsJAMA Oncology, 2022
- Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018JAMA Network Open, 2022
- Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distributionMolecular Oncology, 2020
- Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)Journal of Neuro-Oncology, 2016
- Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrateInternational Journal of Cancer, 2012
- HIF-2α Expression Is Suppressed in SCLC Cells, Which Survive in Moderate and Severe Hypoxia When HIF-1α Is RepressedThe American Journal of Pathology, 2012
- The Transporter Associated With Antigen Processing (TAP): Structural Integrity, Expression, Function, and Its Clinical RelevanceMolecular Medicine, 2001